Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

udy enrolled prior to the fourth quarter of 2013.
  • Phase III study of ibrutinib versus chlorambucil in frontline newly diagnosed elderly CLL/SLL patients, RESONATE™ -2.  This trial is a randomized, multicenter, open-label study of ibrutinib as a monotherapy versus chlorambucil in patients 65 years or older with treatment naïve CLL/SLL. The study design was granted a Special Protocol Assessment (SPA), designed to demonstrate superiority of ibrutinib with the primary endpoint of progression-free survival when compared to chlorambucil. This global study is open and Pharmacyclics plans to enroll 272 patients worldwide. The Company anticipates enrollment for this study will take approximately 18 months to complete. 
  • Phase III study of ibrutinib in combination with bendamustine and rituximab in patients with relapsed or refractory CLL/SLL, HELIOS (CLL3001). This trial is a randomized, multi-center, double blinded, placebo controlled trial of ibrutinib in combination with bendamustine and rituximab in relapsed or refractory CLL/SLL patients who received at least one line of prior systemic therapy. The primary endpoint of the study is to demonstrate a clinically significant improvement in progression-free survival when compared to bendamustine and rituximab. This global study, conducted by Janssen, is open and Janssen plans to enroll 580 patients worldwide.
  • Phase II study, RESONATE™ -17p, which is a single-arm, open-label, multi-center trial using ibrutinib as a monotherapy in patients who have deletion 17p and who did not respond to or relapsed after at least one prior treatment with chemo immunotherapy (a high unmet need population). The primary endpoint of the study will be overall response rate. This global study is open and Pharmacyclics plans to enroll 111 patients worldwide. The Company anticipates enrollment for this study will take approximately 12 months to complete.
  • Phase III study of ibrutinib ver
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related biology technology :

    1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
    2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    7. Pharmasset Reports Fiscal Year End 2011 Financial Results
    8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
    11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/14/2014)... 2014 As pet owners drew up their lists of New ... "Take better care of my furry companion." Nowadays there are pet ... carrying cases to take the little canine or feline darlings along ... to buy some pricey toys at the pet store. But anyone ...
    (Date:1/14/2014)... and BETHESDA, Md. , Jan. ... together with two institutes from the National Institutes of ... for bringing safer, more effective treatments to patients on ... Center for Advancing Translational Sciences (NCATS) and the National ...
    (Date:1/14/2014)... WESTBOROUGH, Mass. , Jan. 14, 2014  RXi ... on discovering, developing and commercializing innovative therapies addressing ... announced that it received the Notice of Allowance ... on its unique self-delivering RNAi compounds (sd-rxRNA®), for ...
    (Date:1/14/2014)... Washington, USA, and Cardiff, UK (PRWEB) January 13, 2014 ... photonics technology development leader with more than 20 years ... society for optics and photonics . Hainsey will serve ... are delighted to have Dr. Hainsey join SPIE as ...
    Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
    ... International, Inc. (OTCQX: DATA), a technology and services company ... industry, today announced the award of a Phase III ... A CRO specializing in dermatology, Symbio will be utilizing ... EDC. In an effort to meet the timelines ...
    ... Reportlinker.com announces that a new market research ... World Bioplastics Industry , ... to increase more than fourfold by 2013 ... plastic resins that are biodegradable or derived from ...
    ... The positive mix lift expected as farmers choose to ... MON ) to reconfirm its commitment to double its ... Hugh Grant will tell investors today. Speaking at the ... launches for its Genuity(TM) SmartStax(TM) corn and Genuity(TM) Roundup ...
    Cached Biology Technology:DATATRAK Signs New Client for Rescue Study 2DATATRAK Signs New Client for Rescue Study 3DATATRAK Signs New Client for Rescue Study 4Reportlinker Adds World Bioplastics Industry 2Reportlinker Adds World Bioplastics Industry 3Reportlinker Adds World Bioplastics Industry 4Reportlinker Adds World Bioplastics Industry 5Reportlinker Adds World Bioplastics Industry 6Reportlinker Adds World Bioplastics Industry 7Reportlinker Adds World Bioplastics Industry 8Reportlinker Adds World Bioplastics Industry 9Monsanto Reconfirms 2010 Guidance and 2012 Financial Commitments on Strength of Larger Expected Launches for Blockbuster Products 2Monsanto Reconfirms 2010 Guidance and 2012 Financial Commitments on Strength of Larger Expected Launches for Blockbuster Products 3Monsanto Reconfirms 2010 Guidance and 2012 Financial Commitments on Strength of Larger Expected Launches for Blockbuster Products 4Monsanto Reconfirms 2010 Guidance and 2012 Financial Commitments on Strength of Larger Expected Launches for Blockbuster Products 5Monsanto Reconfirms 2010 Guidance and 2012 Financial Commitments on Strength of Larger Expected Launches for Blockbuster Products 6Monsanto Reconfirms 2010 Guidance and 2012 Financial Commitments on Strength of Larger Expected Launches for Blockbuster Products 7Monsanto Reconfirms 2010 Guidance and 2012 Financial Commitments on Strength of Larger Expected Launches for Blockbuster Products 8
    (Date:4/22/2014)... 2014) Biotechnology scientists must be aware of the ... licensing guidelines, according to a new paper from Rice ... the current issue of the journal Regenerative Medicine ... U.S. Supreme Court ruling in the case Association for ... genes are unpatentable. The court case and rulings garnered ...
    (Date:4/22/2014)... of Massachusetts Amherst and the Instituto Nacional de Pesquisas ... have discovered a new genus and species of electric ... the Amazonia State of Brazil. , Professor Cristina Cox ... Antnio Alves-Gomes of INPA, describe the new bluntnose knifefish ... of the Natural Sciences of Philadelphia . , ...
    (Date:4/22/2014)... of Kentucky has discovered new methods to build heat ... research, led by Peixuan Guo, professor and William ... of Pharmacy and Markey Cancer Center, is reported in ... Material To Build Robust Structures with Defined Shape and ... Jasinski. , The article, which will appear in a ...
    Breaking Biology News(10 mins):New patenting guidelines are needed for biotechnology 2New patenting guidelines are needed for biotechnology 3New electric fish genus and species discovered in Brazil's Rio Negro 2RNA shows potential as boiling-resistant anionic polymer material for nanoarchitectures 2
    ... SANTA CRUZ, CA--Observations at submarine springs found along the ... preview of the possible fate of coral reef ecosystems ... pH (a measure of acidity) in the water around ... result from the widespread acidification of surface waters that ...
    ... Electronic infrastructures open new horizons for collaboration and acceleration ... such as scratchpads.eu , yield opportunities, ... newly collected data coming from different sources and working ... journal ZooKeys presenting the results ...
    ... FAIRFAX, Va.Researchers have published the largest single patient ... following patients with retrievable inferior vena cava (IVC) ... to the lungs. This study, which is important ... supports existing guidelines developed by the Society of ...
    Cached Biology News:Submarine springs offer preview of ocean acidification effects on coral reefs 2Submarine springs offer preview of ocean acidification effects on coral reefs 3Electronic infrastructures accelerate biodiversity discoveries 2IVC filters: Society of Interventional Radiology leads in patient care, safety, research 2IVC filters: Society of Interventional Radiology leads in patient care, safety, research 3
    Request Info...
    ...
    Candida (IgG) -Ab EIA Sample Size: 5 l...
    Automated centrifuge for the processing of microplates and tubes; can be integrated into automated process using inexpensive robotics due to its unique sample handling platform....
    Biology Products: